公开(公告)号：US20240299521A1

公开(公告)日：2024-09-12

申请号：US18664120

申请日：2024-05-14

申请人： NantBio, Inc.

发明人： Kayvan Niazi ,  Raymond Wong ,  Peter Sieling ,  Philip T. Liu

IPC分类号： A61K39/108 ,  A61K9/00 ,  A61K39/00 ,  C12N15/861

CPC分类号： A61K39/0258 ,  A61K39/0002 ,  C12N15/861 ,  A61K9/0019 ,  A61K2039/605 ,  C12N2770/16034

摘要： Two-component vaccine formulations and methods are contemplated where the vaccine has an adjuvant component and a therapeutic component. The therapeutic component comprises preferably a recombinant therapeutic virus encoding a therapeutic antigen while the adjuvant component comprises a non-host cell or immune stimulating portion thereof. Notably, use of the adjuvant component will result in significant uptake of the therapeutic component into immune competent cells, even in the absence of receptors for entry of the therapeutic component. In addition, such adjuvant also stimulates expression of the therapeutic antigen.

公开(公告)号：US20240342262A1

公开(公告)日：2024-10-17

申请号：US18664198

申请日：2024-05-14

申请人： NantBio, Inc.

发明人： Kayvan Niazi ,  Raymond Wong ,  Peter Sieling ,  Philip T. Liu

IPC分类号： A61K39/108 ,  A61K9/00 ,  A61K39/00 ,  C12N15/861

CPC分类号： A61K39/0258 ,  A61K39/0002 ,  C12N15/861 ,  A61K9/0019 ,  A61K2039/605 ,  C12N2770/16034

摘要： Two-component vaccine formulations and methods are contemplated where the vaccine has an adjuvant component and a therapeutic component. The therapeutic component comprises preferably a recombinant therapeutic virus encoding a therapeutic antigen while the adjuvant component comprises a non-host cell or immune stimulating portion thereof. Notably, use of the adjuvant component will result in significant uptake of the therapeutic component into immune competent cells, even in the absence of receptors for entry of the therapeutic component. In addition, such adjuvant also stimulates expression of the therapeutic antigen.

公开(公告)号：US20240336684A1

公开(公告)日：2024-10-10

申请号：US18750974

申请日：2024-06-21

申请人： NantBio, Inc.

发明人： Clifford Anders Olson ,  Kayvan Niazi ,  Hermes J. Garban ,  Raymond Wong ,  Shiho Tanaka

IPC分类号： C07K16/28 ,  A61K47/68 ,  C07K14/54 ,  C07K14/715 ,  C07K14/725

CPC分类号： C07K16/2803 ,  A61K47/6849 ,  C07K14/5443 ,  C07K14/7051 ,  C07K14/7155 ,  C07K2317/56 ,  C07K2319/30

摘要： Antibodies, fragments thereof, and chimeric proteins comprising same are presented that have specific binding activity against T-cell immunoglobulin mucin receptor 3 (TIM3). Advantageously, contemplated molecules can be used in pharmaceutical compositions for immune therapy, particularly in individuals receiving cancer vaccines and/or checkpoint inhibitor treatment.

公开(公告)号：US12098201B2

公开(公告)日：2024-09-24

申请号：US18302724

申请日：2023-04-18

申请人： NantBio, Inc.

发明人： Clifford Anders Olson ,  Kayvan Niazi ,  Hermes J. Garban ,  Raymond Wong ,  Shiho Tanaka

IPC分类号： C07K16/28 ,  A61K47/68 ,  C07K14/54 ,  C07K14/715 ,  C07K14/725

CPC分类号： C07K16/2803 ,  A61K47/6849 ,  C07K14/5443 ,  C07K14/7051 ,  C07K14/7155 ,  C07K2317/56 ,  C07K2319/30

摘要： Antibodies, fragments thereof, and chimeric proteins comprising the same are presented that have specific binding activity against T-cell immunoglobulin mucin receptor 3 (TIM3). Advantageously, contemplated molecules can be used in pharmaceutical compositions for immune therapy, particularly in individuals receiving cancer vaccines and/or checkpoint inhibitor treatment.

公开(公告)号：US20230287113A1

公开(公告)日：2023-09-14

申请号：US18302724

申请日：2023-04-18

申请人： NantBio, Inc.

发明人： Clifford Anders Olson ,  Kayvan Niazi ,  Hermes J. Garban ,  Raymond Wong ,  Shiho Tanaka

IPC分类号： C07K16/28 ,  A61K47/68 ,  C07K14/725 ,  C07K14/54 ,  C07K14/715

CPC分类号： C07K16/2803 ,  A61K47/6849 ,  C07K14/7051 ,  C07K14/5443 ,  C07K14/7155 ,  C07K2319/30 ,  C07K2317/56

摘要： Antibodies, fragments thereof, and chimeric proteins comprising same are presented that have specific binding activity against T-cell immunoglobulin mucin receptor 3 (TIM3). Advantageously, contemplated molecules can be used in pharmaceutical compositions for immune therapy, particularly in individuals receiving cancer vaccines and/or checkpoint inhibitor treatment.

公开(公告)号：US20220370587A1

公开(公告)日：2022-11-24

申请号：US17684121

申请日：2022-03-01

申请人： NantBio, Inc.

发明人： Kayvan Niazi ,  Raymond Wong ,  Peter Sieling ,  Philip T. Liu

IPC分类号： A61K39/108 ,  A61K39/00 ,  C12N15/861

摘要： Two-component vaccine formulations and methods are contemplated where the vaccine has an adjuvant component and a therapeutic component. The therapeutic component comprises preferably a recombinant therapeutic virus encoding a therapeutic antigen while the adjuvant component comprises a non-host cell or immune stimulating portion thereof. Notably, use of the adjuvant component will result in significant uptake of the therapeutic component into immune competent cells, even in the absence of receptors for entry of the therapeutic component. In addition, such adjuvant also stimulates expression of the therapeutic antigen.

公开(公告)号：US11298414B2

公开(公告)日：2022-04-12

申请号：US16536962

申请日：2019-08-09

申请人： NANTBIO, INC.

发明人： Kayvan Niazi ,  Raymond Wong ,  Peter Sieling ,  Philip T. Liu

IPC分类号： C12N15/861 ,  A61K39/108 ,  A61K39/00 ,  A61K9/00

摘要： Two-component vaccine formulations and methods are contemplated where the vaccine has an adjuvant component and a therapeutic component. The therapeutic component comprises preferably a recombinant therapeutic virus encoding a therapeutic antigen while the adjuvant component comprises a non-host cell or immune stimulating portion thereof. Notably, use of the adjuvant component will result in significant uptake of the therapeutic component into immune competent cells, even in the absence of receptors for entry of the therapeutic component. In addition, such adjuvant also stimulates expression of the therapeutic antigen.

公开(公告)号：US11753467B2

公开(公告)日：2023-09-12

申请号：US17587546

申请日：2022-01-28

申请人： NantBio, Inc.

发明人： Clifford Anders Olson ,  Kayvan Niazi ,  Hermes J. Garban ,  Raymond Wong ,  Shiho Tanaka

IPC分类号： C07K16/28 ,  A61K47/68 ,  C07K14/725 ,  C07K14/54 ,  C07K14/715

CPC分类号： C07K16/2803 ,  A61K47/6849 ,  C07K14/5443 ,  C07K14/7051 ,  C07K14/7155 ,  C07K2317/56 ,  C07K2319/30

摘要： Antibodies, fragments thereof, and chimeric proteins comprising same are presented that have specific binding activity against T-cell immunoglobulin mucin receptor 3 (TIM3). Advantageously, contemplated molecules can be used in pharmaceutical compositions for immune therapy, particularly in individuals receiving cancer vaccines and/or checkpoint inhibitor treatment.

公开(公告)号：US20220235130A1

公开(公告)日：2022-07-28

申请号：US17587546

申请日：2022-01-28

申请人： NantBio, Inc.

发明人： Clifford Anders Olson ,  Kayvan Niazi ,  Hermes J. Garban ,  Raymond Wong ,  Shiho Tanaka

IPC分类号： C07K16/28 ,  A61K47/68 ,  C07K14/725 ,  C07K14/715 ,  C07K14/54

摘要： Antibodies, fragments thereof, and chimeric proteins comprising same are presented that have specific binding activity against T-cell immunoglobulin mucin receptor 3 (TIM3). Advantageously, contemplated molecules can be used in pharmaceutical compositions for immune therapy, particularly in individuals receiving cancer vaccines and/or checkpoint inhibitor treatment.